Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Stoke Therapeutics Q2 EPS $(0.40) Beats $(0.46) Estimate, Sales $13.817M Beat $9.967M Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:02pm
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.46) by 13.61 percent. This is a 13.04 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $13.817 million which beat the analyst consensus estimate of $9.967 million by 38.63 percent. This is a 186.01 percent increase over sales of $4.831 million the same period last year.

Posted In: STOK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist